On the public citation graph
BAFF rs9514828 gene polymorphism and the risk of the development of inhibitors in children with severe haemophilia A
0 signed · 44 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/ajh.23957openalex-snapshot
Impact of inhibitors on hemophilia a mortality in the U nited S tates
inferredcites →https://doi.org/10.1002/elps.201000216openalex-snapshot
Recombinant clotting factor VIII concentrates: Heterogeneity and high‐purity evaluation
inferredcites →https://doi.org/10.1007/s12016-009-8117-2openalex-snapshot
A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A
inferredcites →https://doi.org/10.1016/j.jaut.2013.04.005openalex-snapshot
B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome
inferredcites →https://doi.org/10.1016/j.jbspin.2011.05.020openalex-snapshot
Elevated BAFF (BLyS) and APRIL in Juvenile idiopathic arthritis patients: Relation to clinical manifestations and disease activity
inferredcites →https://doi.org/10.1016/s0140-6736(10)61354-2openalex-snapshot
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1038/sj.gene.6363923openalex-snapshot
Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis
inferredcites →https://doi.org/10.1055/s-0029-1245105openalex-snapshot
The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment
inferredcites →https://doi.org/10.1056/nejmoa067659openalex-snapshot
Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
inferredcites →https://doi.org/10.1056/nejmoa1610528openalex-snapshot
Overexpression of the Cytokine BAFF and Autoimmunity Risk
inferredcites →https://doi.org/10.1056/nejmoa1703068openalex-snapshot
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
inferredcites →https://doi.org/10.1080/08830185.2016.1276903openalex-snapshot
Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases
inferredcites →https://doi.org/10.1093/rheumatology/ken246openalex-snapshot
Polymorphism in the 5′ regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjögren's syndrome
inferredcites →https://doi.org/10.1093/rheumatology/kes344openalex-snapshot
Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients
inferredcites →https://doi.org/10.1111/cen.13872openalex-snapshot
Analysis of BAFF gene polymorphisms in UK Graves’ disease patients
inferredcites →https://doi.org/10.1111/hae.12096openalex-snapshot
Cytokine profile and FVIII inhibitors development in haemophilia A
inferredcites →https://doi.org/10.1111/hae.13424openalex-snapshot
Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review
inferredcites →https://doi.org/10.1111/hae.13747openalex-snapshot
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies
inferredcites →https://doi.org/10.1111/j.1365-2141.2006.06431.xopenalex-snapshot
High‐level serum B‐cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura
inferredcites →https://doi.org/10.1111/j.1365-2516.2009.02197.xopenalex-snapshot
Assessing risk factors: prevention of inhibitors in haemophilia
inferredcites →https://doi.org/10.1111/j.1365-2516.2011.02679.xopenalex-snapshot
Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A
inferredcites →https://doi.org/10.1111/j.1538-7836.2005.01375.xopenalex-snapshot
Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?
inferredcites →https://doi.org/10.1111/j.1538-7836.2007.02290.xopenalex-snapshot
Polymorphisms in the CTLA‐4 gene and inhibitor development in patients with severe hemophilia A
inferredcites →https://doi.org/10.1111/j.1538-7836.2009.03636.xopenalex-snapshot
Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia A
inferredcites →https://doi.org/10.1111/j.1744-313x.2008.00778.xopenalex-snapshot
TNF, IFNG, IL6, IL10 and TGFB1 gene polymorphisms in South and Southeast Brazil
inferredcites →https://doi.org/10.1172/jci142906openalex-snapshot
B cell–activating factor modulates the factor VIII immune response in hemophilia A
inferredcites →https://doi.org/10.1182/blood-2005-09-3918openalex-snapshot
Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A
inferredcites →https://doi.org/10.1182/blood-2006-05-024711openalex-snapshot
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A
inferredcites →https://doi.org/10.1182/blood-2011-09-379453openalex-snapshot
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
inferredcites →https://doi.org/10.1182/blood-2012-07-444877openalex-snapshot
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients
inferredcites →https://doi.org/10.1182/blood-2012-09-457036openalex-snapshot
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
inferredcites →https://doi.org/10.1186/1750-1172-7-24openalex-snapshot
Past, present and future of hemophilia: a narrative review
inferredcites →https://doi.org/10.1186/ar1884openalex-snapshot
No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome
inferredcites →https://doi.org/10.1186/s13023-018-0929-9openalex-snapshot
Inhibitor clinical burden of disease: a comparative analysis of the CHESS data
inferredcites →https://doi.org/10.17615/tepe-nx20openalex-snapshot
The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A
inferredcites →https://doi.org/10.3324/haematol.2015.137067openalex-snapshot
von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII
inferredcites →https://doi.org/10.3389/fimmu.2018.02285openalex-snapshot
BAFF and BAFF-Receptor in B Cell Selection and Survival
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4789895openalex-extracted
Maternal Microchimerism Promotes Tolerance Induction Toward Factor VIII in Severe Haemophilia a Children with Inhibitors
inferred← citeshttps://doi.org/10.12677/acm.2024.143978openalex-snapshot
Recent Advances in Genetic and Non-Genetic Factors Related to the Development of Hemophilia Inhibitors
inferred← citeshttps://doi.org/10.1515/med-2025-1294openalex-snapshot
Investigation of the pathogenic variants induced Sjogren’s syndrome in Turkish population
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1921432openalex-snapshot
Maternal microchimerism accelerates immune tolerance induction to factor VIII in children with hemophilia A and FVIII inhibitors
inferred← citeshttps://doi.org/10.4103/ejh.ejh_9_25openalex-snapshot
Vascular endothelial growth factor A as an early diagnostic marker of hemophilic arthropathy in children with severe hemophilia A
inferred← citeshttps://doi.org/10.70675/fb0159d0zb989z4a8dz9ca2zc27e4e44e055openalex-snapshot
Eradication of FVIII inhibitors in patients with hemophilia A
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.